Definium Therapeutics (DFTX) Institutional Ownership
13F filers reported holding 45.7% of Definium Therapeutics (DFTX) shares as of Sep 30, 2026, across 257 filers.
- Held by 13F filers
- 45.7%
- Sep 30, 2026
- 13F filers
- 257
- quarter ended Sep 30, 2026
- 13F value
- $2.4B
- 62.5M shares
- Quarter's fund flow
- Mild accumulation
- 46 new · 44 closed
Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.
| Date | Name | Role | Type | Shares | Price** | SEC filing |
|---|---|---|---|---|---|---|
| Sep 25, 2026 | Karlin Dan | Chief Medical Officer | Disposed · Open-market sale | 10,853Common Shares | $36.57 | ↗ |
| Sep 25, 2026 | Barrow Robert | Chief Executive Officer | Disposed · Open-market sale | 31,550Common Shares | $36.57 | ↗ |
| Sep 25, 2026 | Wiley Matthew T. | Chief Commercial Officer | Disposed · Open-market sale | 3,097Common Shares | $36.57 | ↗ |
| Sep 25, 2026 | Sullivan Mark | Chief Legal Officer | Disposed · Open-market sale | 14,051Common Shares | $36.57 | ↗ |
| Sep 25, 2026 | Roberts Brandi | Chief Financial Officer | Disposed · Open-market sale | 3,377Common Shares | $36.57 | ↗ |
| Sep 18, 2026 | Krebs Andreas | director | Acquired · Option exercise | 1,629Common Shares | $35.52 | ↗ |
| Sep 18, 2026 | Krebs Andreas | director | Disposed · Option exercise | 1,629Stock Option (Right to Buy) | — | ↗ |
| Sep 18, 2026 | Vallone Carol A | director | Acquired · Option exercise | 1,086Common Shares | $35.52 | ↗ |
| Sep 18, 2026 | Vallone Carol A | director | Disposed · Option exercise | 1,086Stock Option (Right to Buy) | — | ↗ |
| Sep 14, 2026 | Karlin Dan | Chief Medical Officer | Acquired · Grant / award | 200,000Common Shares | — | ↗ |
| Sep 14, 2026 | Wiley Matthew T. | Chief Commercial Officer | Acquired · Grant / award | 125,000Common Shares | — | ↗ |
| Sep 14, 2026 | Sullivan Mark | Chief Legal Officer | Acquired · Grant / award | 125,000Common Shares | — | ↗ |
| Sep 14, 2026 | Roberts Brandi | Chief Financial Officer | Acquired · Grant / award | 125,000Common Shares | — | ↗ |
| Sep 14, 2026 | Barrow Robert | Chief Executive Officer | Acquired · Grant / award | 750,000Common Shares | — | ↗ |
| Sep 3, 2026 | Barrow Robert | Chief Executive Officer | Disposed · Open-market sale | 19,023Common Shares | $37.94 | ↗ |
| Sep 2, 2026 | Barrow Robert | Chief Executive Officer | Acquired · Grant / award | 40,000Common Shares | — | ↗ |
| Aug 12, 2026 | Barrow Robert | Chief Executive Officer | Acquired · Grant / award | 375,000Common Shares | — | ↗ |
| Aug 12, 2026 | Karlin Dan | Chief Medical Officer | Acquired · Grant / award | 100,000Common Shares | — | ↗ |
| Aug 12, 2026 | Sullivan Mark | Chief Legal Officer | Acquired · Grant / award | 62,500Common Shares | — | ↗ |
| Aug 12, 2026 | Wiley Matthew T. | Chief Commercial Officer | Acquired · Grant / award | 62,500Common Shares | — | ↗ |
* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.
** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.
Common questions
How much of Definium Therapeutics do institutions hold?
13F filers reported holding 45.7% of Definium Therapeutics' shares as of Sep 30, 2026, across 257 filers.
How many 13F filers hold Definium Therapeutics?
Definium Therapeutics was held by 257 13F filers as of Sep 30, 2026.
Not investment advice.

